[Abstract + References] How safe is switching antiepileptic drug manufacturers?

A nationwide German study of prescription data has demonstrated that switching to an antiepileptic drug from a different manufacturer increases the risk of seizure relapse. This finding sparks a debate about the reason for seizure worsening after switching and whether or not it is a pharmacological issue.

References

1. 1.

   Lang, J. D. et al. Switching the manufacturer of anti-epileptic drugs is associated with higher risk of seizures. Ann. Neurol.https://doi.org/10.1002/ana.25353 (2018).

   • Show contextfor reference 1
   • • Article
     • PubMed
     • Google Scholar
2. 2.

   Davit, B. M. et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann. Pharmacother. 43, 1583–1597 (2009).

   • Show contextfor reference 2
   • • CAS
     • Article
     • Google Scholar
3. 3.

   Krauss, G. L. et al. Assessing bioequivalence of generic antiepilepsy drugs. Ann. Neurol. 70, 221–228 (2011).

   • Show contextfor reference 3
   • • CAS
     • Article
     • Google Scholar
4. 4.

   Labiner, D. M. et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 74, 1566–1574 (2010).

   • Show contextfor reference 4
   • • CAS
     • Article
     • Google Scholar
5. 5.

   Andermann, F. et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 48, 464–469 (2007).

   • Show contextfor reference 5
   • • CAS
     • Article
     • Google Scholar
6. 6.

   Ting, T. J. et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia 56, 1415–1424 (2015).

   • Show contextfor reference 6
   • • CAS
     • Article
     • Google Scholar
7. 7.

   Privitera, M. D. et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol. 15, 365–372 (2016).

   • Show contextfor reference 7
   • • CAS
     • Article
     • Google Scholar
8. 8.

   Gollwitzer, S. et al. Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study. Neurology 87, 466–472 (2016).

   • Show contextfor reference 8
   • • CAS
     • Article
     • Google Scholar
9. 9.

   Kesselheim, A. S. et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern. Med. 173, 202–208 (2013).

   • Show contextfor reference 9
   • • Article
     • Google Scholar
10. 10.

    Holtkamp, M. & Theodore, W. H. Generic antiepileptic drugs — safe or harmful in patients with epilepsy? Epilepsia 59, 1273–1281 (2018).

    • Show contextfor reference 10
    • • Article
      • Google Scholar

via How safe is switching antiepileptic drug manufacturers? | Nature Reviews Neurology